Technique Developed to Help Clinicians Treat Early Brain Glioma Tumors
By MedImaging International staff writers Posted on 27 Dec 2015 |
A new technique for detecting and treating deadly brain tumors earlier using a nanotechnology Magnetic Resonance Imaging (MRI) contrast agent has been developed.
The agent can pass through the blood-brain barrier and provides opportunities to treat normally fatal gliomas. Patients with cancerous gliomas have a median survival rate of 14 months after they are diagnosed.
The new approach was developed by researchers at the Department of Neurosurgery of Penn State College of Medicine (Hershey, PA, USA), and was published in the Journal of Neuro-Oncology.
Current treatment options for patients with malignant glioma are surgery, chemotherapy, radiation therapy but the cancer often returns, surviving initial treatments, and follow-up MRI scans often are unable to catch the tumors in time. Existing MRI contrast agents can only find tumors after they are large enough to damage the blood-brain barrier. The Penn State research team found a way to created "smart fat cells" or liposomes that are able to pass the blood-brain barrier in mice, and find cancerous gliomas earlier. The liposomes work together with Magnevist, a common MRI contrast agent, and are also studded with proteins that target receptors on glioma cells. According to the researchers, smart fat cells may be used in the future to deliver chemotherapeutic drugs, and contrast agents, to brain tumor patients, to detect and remove cancer cells.
James Connor, distinguished professor of neurosurgery, said "Patients typically don't die from the tumor they initially presented with. Rather, they die from new tumors that come back in other parts of the brain. The goal is to be able to get down to detecting single cancer cells. Ultrasound, with all of its good qualities, is disruptive to the blood-brain barrier, whereas we can get an agent to cross it without causing disruption."
Related Links:
Penn State College of Medicine
The agent can pass through the blood-brain barrier and provides opportunities to treat normally fatal gliomas. Patients with cancerous gliomas have a median survival rate of 14 months after they are diagnosed.
The new approach was developed by researchers at the Department of Neurosurgery of Penn State College of Medicine (Hershey, PA, USA), and was published in the Journal of Neuro-Oncology.
Current treatment options for patients with malignant glioma are surgery, chemotherapy, radiation therapy but the cancer often returns, surviving initial treatments, and follow-up MRI scans often are unable to catch the tumors in time. Existing MRI contrast agents can only find tumors after they are large enough to damage the blood-brain barrier. The Penn State research team found a way to created "smart fat cells" or liposomes that are able to pass the blood-brain barrier in mice, and find cancerous gliomas earlier. The liposomes work together with Magnevist, a common MRI contrast agent, and are also studded with proteins that target receptors on glioma cells. According to the researchers, smart fat cells may be used in the future to deliver chemotherapeutic drugs, and contrast agents, to brain tumor patients, to detect and remove cancer cells.
James Connor, distinguished professor of neurosurgery, said "Patients typically don't die from the tumor they initially presented with. Rather, they die from new tumors that come back in other parts of the brain. The goal is to be able to get down to detecting single cancer cells. Ultrasound, with all of its good qualities, is disruptive to the blood-brain barrier, whereas we can get an agent to cross it without causing disruption."
Related Links:
Penn State College of Medicine
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer